vs

Side-by-side financial comparison of FIRST MERCHANTS CORP (FRME) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($225.6M vs $157.1M, roughly 1.4× FIRST MERCHANTS CORP). Organogenesis Holdings Inc. runs the higher net margin — 19.4% vs 17.9%, a 1.5% gap on every dollar of revenue. Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs -0.9%).

First Merchants Corporation is a financial holding company in Central Indiana, headquartered in Muncie, Indiana. The Corporation includes First Merchants Bank and First Merchants Private Wealth Advisors. The company is listed on the NASDAQ as FRME. As of March 2023, total asset size of First Merchants Corporation was $18.2 billion. First Merchants offers commercial banking, personal banking, and investment advisor services.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

FRME vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.4× larger
ORGO
$225.6M
$157.1M
FRME
Higher net margin
ORGO
ORGO
1.5% more per $
ORGO
19.4%
17.9%
FRME
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
-0.9%
FRME

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
FRME
FRME
ORGO
ORGO
Revenue
$157.1M
$225.6M
Net Profit
$28.2M
$43.7M
Gross Margin
Operating Margin
28.1%
Net Margin
17.9%
19.4%
Revenue YoY
78.1%
Net Profit YoY
-49.1%
469.5%
EPS (diluted)
$0.45
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FRME
FRME
ORGO
ORGO
Q1 26
$157.1M
Q4 25
$172.2M
$225.6M
Q3 25
$166.1M
$150.9M
Q2 25
$164.3M
$101.0M
Q1 25
$160.3M
$86.7M
Q4 24
$177.1M
$126.7M
Q3 24
$156.0M
$115.2M
Q2 24
$159.9M
$130.2M
Net Profit
FRME
FRME
ORGO
ORGO
Q1 26
$28.2M
Q4 25
$57.1M
$43.7M
Q3 25
$56.8M
$21.6M
Q2 25
$56.8M
$-9.4M
Q1 25
$55.3M
$-18.8M
Q4 24
$64.3M
$7.7M
Q3 24
$49.2M
$12.3M
Q2 24
$39.9M
$-17.0M
Gross Margin
FRME
FRME
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
FRME
FRME
ORGO
ORGO
Q1 26
Q4 25
38.0%
28.1%
Q3 25
39.3%
13.7%
Q2 25
39.6%
-12.5%
Q1 25
39.4%
-30.9%
Q4 24
43.3%
8.1%
Q3 24
36.1%
5.4%
Q2 24
27.5%
-10.7%
Net Margin
FRME
FRME
ORGO
ORGO
Q1 26
17.9%
Q4 25
33.1%
19.4%
Q3 25
34.2%
14.3%
Q2 25
34.6%
-9.3%
Q1 25
34.5%
-21.7%
Q4 24
36.3%
6.1%
Q3 24
31.5%
10.7%
Q2 24
25.0%
-13.1%
EPS (diluted)
FRME
FRME
ORGO
ORGO
Q1 26
$0.45
Q4 25
$0.98
$0.31
Q3 25
$0.98
$0.11
Q2 25
$0.98
$-0.10
Q1 25
$0.94
$-0.17
Q4 24
$1.09
$0.05
Q3 24
$0.84
$0.09
Q2 24
$0.68
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FRME
FRME
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$93.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.7B
$300.1M
Total Assets
$21.1B
$598.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FRME
FRME
ORGO
ORGO
Q1 26
Q4 25
$93.7M
Q3 25
$63.7M
Q2 25
$73.1M
Q1 25
$110.0M
Q4 24
$135.6M
Q3 24
$94.3M
Q2 24
$89.9M
Total Debt
FRME
FRME
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
FRME
FRME
ORGO
ORGO
Q1 26
$2.7B
Q4 25
$2.5B
$300.1M
Q3 25
$2.4B
$255.1M
Q2 25
$2.3B
$233.2M
Q1 25
$2.3B
$242.9M
Q4 24
$2.3B
$262.9M
Q3 24
$2.3B
$278.5M
Q2 24
$2.2B
$263.5M
Total Assets
FRME
FRME
ORGO
ORGO
Q1 26
$21.1B
Q4 25
$19.0B
$598.7M
Q3 25
$18.8B
$509.8M
Q2 25
$18.6B
$461.1M
Q1 25
$18.4B
$467.4M
Q4 24
$18.3B
$497.9M
Q3 24
$18.3B
$446.3M
Q2 24
$18.3B
$443.2M
Debt / Equity
FRME
FRME
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FRME
FRME
ORGO
ORGO
Operating Cash FlowLast quarter
$39.4M
Free Cash FlowOCF − Capex
$34.8M
FCF MarginFCF / Revenue
15.4%
Capex IntensityCapex / Revenue
2.1%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FRME
FRME
ORGO
ORGO
Q1 26
Q4 25
$283.6M
$39.4M
Q3 25
$87.6M
$3.1M
Q2 25
$53.7M
$-32.9M
Q1 25
$61.7M
$-19.9M
Q4 24
$266.2M
$10.9M
Q3 24
$76.8M
$8.7M
Q2 24
$63.0M
$4.7M
Free Cash Flow
FRME
FRME
ORGO
ORGO
Q1 26
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
FCF Margin
FRME
FRME
ORGO
ORGO
Q1 26
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Capex Intensity
FRME
FRME
ORGO
ORGO
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Cash Conversion
FRME
FRME
ORGO
ORGO
Q1 26
Q4 25
4.97×
0.90×
Q3 25
1.54×
0.14×
Q2 25
0.94×
Q1 25
1.11×
Q4 24
4.14×
1.43×
Q3 24
1.56×
0.71×
Q2 24
1.58×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FRME
FRME

Net Interest Income$151.3M96%
Noninterest Income$5.8M4%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons